Global Huntington's Disease Therapeutics Market 2017-2021

  • ID: 4368882
  • Report
  • Region: Global
  • 86 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5
Analysts forecast the global huntington’s disease therapeutics market to grow at a CAGR of 14.75% during the period 2017-2021

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Horizon Pharma
  • Intellect Neurosciences
  • Prana Biotechnology
  • Sangamo Therapeutics
  • MORE
About Huntington’s Disease Therapeutics

Analysts forecast the global huntington’s disease therapeutics market to grow at a CAGR of 14.75% during the period 2017-2021

HD is an inherited condition that leads to destruction of nerve cells or neurons. The damage to nerve cells usually causes change in personality, mood swings, irritability and altered behavior. The global HD therapeutics market was witnessing a high unmet demand for disease modifying drug, in the presence of only one approved therapy, Xenazine, and the off-label use of various different therapeutics. The introduction of AUSTEDO in the market will have a significant impact on the market growth, thereby changing the market dynamics.

Covered in this report

The report covers the present scenario and the growth prospects of the global huntington’s disease therapeutics market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off label drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
Global Huntington’s Disease Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Prana Biotechnology
  • Teva Pharmaceutical Industries
Other Prominent Vendors
  • Intellect Neurosciences
  • Horizon Pharma
  • Sangamo Therapeutics
  • Vertex Pharmaceuticals
Market Drivers
  • Early onset of disease symptoms, increases the demand for HD therapeutics
  • For a full, detailed list, view the full report
Market Challenges
  • Increase in alternative programs for management of mental disorders
  • For a full, detailed list, view the full report
Market Trends
  • Advances in biomedical sciences
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.

Research methodology is based on extensive primary and secondary research:
  • Primary research includes in-depth interviews with industry experts, vendors, resellers and customers
  • Secondary research includes the publisher's platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by government agencies
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Horizon Pharma
  • Intellect Neurosciences
  • Prana Biotechnology
  • Sangamo Therapeutics
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: HD: An introduction

PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: Pipeline

PART 08: Market segmentation by drug-class
  • Market scenario by drug-class
  • Antidopaminergics
  • Anticonvulsants
  • Antipsychotics
  • Antidepressants
  • Others
PART 09: Geographical segmentation
  • Market segmentation by geography
  • HD therapeutics market in Americas
  • HD therapeutics market in EMEA
  • HD therapeutics market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Advances in biomedical sciences
  • Focus on regenerative therapies for mental disorders
  • Rising public interest toward mental health
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Prana Biotechnology
  • Teva Pharmaceutical Industries
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Parts of brain affected by HD
Exhibit 02: Key facts about HD
Exhibit 03: Prevalence and incidence of HD
Exhibit 04: Neurotransmitter involved in pathogenesis of HD
Exhibit 05: Market snapshot
Exhibit 06: Global HD therapeutics market 2016-2021 ($ millions)
Exhibit 07: Opportunity analysis of global HD therapeutics market
Exhibit 08: Five forces analysis
Exhibit 09: Pipeline landscape based on number of molecules 2016
Exhibit 10: HD: Key clinical trials
Exhibit 11: Segmentation of global HD therapeutics market by drug-class
Exhibit 12: Global HD therapeutics market share by drug-class
Exhibit 13: Antidopaminergics used in HD
Exhibit 14: Uses and side-effects of antidopaminergics
Exhibit 15: Global HD therapeutics market by antidopaminergics 2016-2021 ($ millions)
Exhibit 16: Pharmacologic approach for the treatment of chorea
Exhibit 17: Anticonvulsants used in HD
Exhibit 18: Uses and side-effects of anticonvulsants
Exhibit 19: Global HD therapeutics market by anticonvulsants 2016-2021 ($ millions)
Exhibit 20: Antipsychotics used in HD
Exhibit 21: Uses and side-effects of antipsychotics
Exhibit 22: Global HD therapeutics market by antipsychotics 2016-2021 ($ millions)
Exhibit 23: Symptoms of depression associated with HD
Exhibit 24: Global HD therapeutics market by antidepressants 2016-2021 ($ millions)
Exhibit 25: Symptoms of mania associated with HD
Exhibit 26: Global HD therapeutics market share by geography 2016 and 2021
Exhibit 27: Global HD therapeutics market revenue by geography 2016-2021
Exhibit 28: Global HD therapeutics market share by geography 2016-2021
Exhibit 29: HD therapeutics market scenario in different geographies
Exhibit 30: Market scenario in Americas
Exhibit 31: HD therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 32: Market scenario in EMEA
Exhibit 33: HD therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 34: Market scenario in APAC
Exhibit 35: HD therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 36: Planned clinical trials of iPS cell-based therapies
Exhibit 37: Competitive structure analysis of global HD therapeutics market 2016
Exhibit 38: F. Hoffmann-La Roche: Key highlights
Exhibit 39: F. Hoffmann-La Roche: Strength assessment
Exhibit 40: F. Hoffmann-La Roche: Strategy assessment
Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 42: H. Lundbeck: Key highlights
Exhibit 43: H. Lundbeck: Strength assessment
Exhibit 44: H. Lundbeck: Strategy assessment
Exhibit 45: H. Lundbeck: Opportunity assessment
Exhibit 46: Prana Biotechnology: Key highlights
Exhibit 47: Prana Biotechnology: Strength assessment
Exhibit 48: Prana Biotechnology: Strategy assessment
Exhibit 49: Prana Biotechnology: Opportunity assessment
Exhibit 50: Teva Pharmaceuticals: Key highlights
Exhibit 51: Teva Pharmaceuticals: Strength assessment
Exhibit 52: Teva Pharmaceuticals: Strategy assessment
Exhibit 53: Teva Pharmaceuticals: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Horizon Pharma
  • Intellect Neurosciences
  • Prana Biotechnology
  • Sangamo Therapeutics
  • MORE
New Research Report - Global Huntington’s Disease Therapeutics Market 2017-2021

The publisher recognizes the following companies as the key players in the global huntington’s disease therapeutics market: F. Hoffmann-La Roche, H. Lundbeck, Prana Biotechnology, and Teva Pharmaceutical Industries.

Other Prominent Vendors in the market are: Intellect Neurosciences, Horizon Pharma, Sangamo Therapeutics, and Vertex Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “One trend in the market is advances in biomedical sciences. In the past few decades, the advancement in science and introduction of nanotechnologies in the global pharmaceutical market, have revolutionized the development of medicines. With better understanding of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy, thus producing disease modifying drugs.”

According to the report, one driver in the market is early onset of disease symptoms, increases the demand for HD therapeutics. The prevalence rate of HD is equal in both males and females, and the disease affects humans of all ethnic and racial groups. The disease symptoms first appear in the mid-life, between the ages of 25-45 years. In some cases, the disease symptoms may appear as early as the age of two years in children. Children suffering from HD rarely live to their adulthood. Since, the etiology of HD disease is genetic in origin, there are always 50/50 chances of inheriting the mutated gene from the affected parents.

Further, the report states that one challenge in the market is increase in alternative programs for management of mental disorders. The currently available HD therapeutics are unsuccessful in eliminating the symptoms of most of the mental disorders and are known to cause severe side effects such as weight gain, sedation, prolongation of the corrected QT (QTc) interval, and fatal blood dyscrasias. Thus, demonstrating a high unmet need for the development of novel therapeutics that can fill the gap between diagnosis and adherence to drug therapies. This, in turn, has led to the high adoption of alternative programs for the management of HD.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Prana Biotechnology
  • Teva Pharmaceutical Industries
  • Intellect Neurosciences
  • Horizon Pharma
  • Sangamo Therapeutics
  • Vertex Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll